---

Bill Title: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Spectrum: Partisan Bill (Republican 2-0)

Status: (Introduced) 2023-10-06 - Referred to the Subcommittee on Health. [HB5850 Detail]

Download: US_Congress-2023-HB5850-Introduced.pdf

---